Molecular Dx Company XDx Files IPO Papers; Funds May Pay for Acquisitions | GenomeWeb
NEW YORK (GenomeWeb News) — Molecular diagnostics company XDx has filed an initial public offering prospectus with the US Securities and Exchange Commission.
XDx, which develops diagnostics for immune-mediated disorders in patients who require long-term monitoring, said it plans to use the funds generated by the offering to expand infrastructure, propel R&D to support current and future tests, increase sales, marketing, and research staff, and expand facilities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.